De novo drug design

Area of Science:

• Medicinal Chemistry
• Computational Chemistry
• Drug Discovery

Background:

• Computer-assisted molecular design (CAMD) is crucial for identifying novel drug candidates and optimizing lead structures.
• Historically, the synthetic feasibility of CAMD-generated compounds has been overlooked, but is now a key research focus.
• Fragment-based techniques are emerging as a powerful approach within de novo drug design.

Purpose of the Study:

• To review state-of-the-art software for de novo drug design.
• To emphasize fragment-based methods that yield druglike and synthetically accessible compounds.
• To highlight the role of scoring functions in predicting compound reactivity and potency.

Main Methods:

• Review of current de novo drug design software.
• Focus on fragment-based approaches.
• Discussion of scoring functions for predicting chemical properties.

Main Results:

• Fragment-based de novo design can generate druglike compounds with synthetic accessibility.
• Scoring functions are vital for predicting compound reactivity and biological potency.
• Practical validation studies confirm the efficacy of rule-based fragment assembly.

Conclusions:

• De novo drug design, particularly fragment-based methods, is advancing with a focus on synthetic feasibility.
• Effective scoring functions are essential for guiding the design of viable drug candidates.
• Rule-based fragment assembly offers a promising route to novel, synthesizable compounds with desired biological activities.